Similar articles

• Addressing the Evidence to Practice Gap: What to Expect From International Antipsychotic Dose Reduction Studies in the Tapering Anti-Psychotics and Evaluating Recovery Consortium.

  Koops S, Allott K, de Haan L, Chen E, Hui C, Killackey E, Long M, Moncrieff J, Sommer I, Stürup AE, Wunderink L, Begemann M; TAPER international research consortium. Koops S, et al. Schizophr Bull. 2024 Jan 1;50(1):5-8. doi: 10.1093/schbul/sbad112. Schizophr Bull. 2024. PMID: 37625022 Free PMC article. No abstract available.
• Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.

  Verhoef LM, van den Bemt BJ, van der Maas A, Vriezekolk JE, Hulscher ME, van den Hoogen FH, Jacobs WC, van Herwaarden N, den Broeder AA. Verhoef LM, et al. Cochrane Database Syst Rev. 2019 May 24;5(5):CD010455. doi: 10.1002/14651858.CD010455.pub3. Cochrane Database Syst Rev. 2019. PMID: 31125448 Free PMC article.
• A pharmacy led program to review anti-psychotic prescribing for people with dementia.

  Child A, Clarke A, Fox C, Maidment I. Child A, et al. BMC Psychiatry. 2012 Sep 25;12:155. doi: 10.1186/1471-244X-12-155. BMC Psychiatry. 2012. PMID: 23006528 Free PMC article.
• Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables.

  Meaney AM, O'Keane V. Meaney AM, et al. Schizophr Res. 2007 Jul;93(1-3):136-43. doi: 10.1016/j.schres.2007.01.013. Epub 2007 Apr 30. Schizophr Res. 2007. PMID: 17467954 Clinical Trial.
• Implementing gradual, hyperbolic tapering of long-acting injectable antipsychotics by prolonging the inter-dose interval: an in silico modelling study.

  O'Neill JR, Taylor DM, Horowitz MA. O'Neill JR, et al. Ther Adv Psychopharmacol. 2023 Sep 13;13:20451253231198463. doi: 10.1177/20451253231198463. eCollection 2023. Ther Adv Psychopharmacol. 2023. PMID: 37719449 Free PMC article. Review.